Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy01:26

Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy

420
Continuous Renal Replacement Therapy (CRRT) is an essential intervention for patients experiencing severe kidney dysfunction. This therapy offers a continuous mechanism for removing fluids and toxins from the bloodstream, leveraging the patient’s blood pressure to facilitate filtration through a specialized filter. This method contrasts with intermittent dialysis, providing a gentler and more consistent removal of waste products and excess fluid, which is particularly beneficial in...
420
Continuous Renal Replacement Therapy01:30

Continuous Renal Replacement Therapy

2.4K
Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...
2.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Novel, complex configurations of the <i>MARCHF6</i> repeat expansion associated with progressive myoclonic epilepsy and familial adult myoclonic epilepsy.

Brain communications·2025
Same author

Role of Endogenous Galectin-3 on Cell Biology of Immortalized Retinal Pigment Epithelial Cells In Vitro.

International journal of molecular sciences·2025
Same author

Leber's hereditary optic neuropathy - current status of idebenone and gene replacement therapies.

Medizinische Genetik : Mitteilungsblatt des Berufsverbandes Medizinische Genetik e.V·2025
Same author

Correction: RPE65-associated retinal dystrophies: phenotypes and treatment effects with voretigene neparvovec.

Klinische Monatsblatter fur Augenheilkunde·2025
Same author

Intravitreal Enzyme Replacement Therapy Slows Retinopathy in Late Infantile Ceroid Lipofuscinosis Type 2.

Neuropediatrics·2025
Same author

A conserved role for ALG10/ALG10B and the <i>N</i> -glycosylation pathway in the sleep-epilepsy axis.

medRxiv : the preprint server for health sciences·2024

Related Experiment Video

Updated: May 6, 2026

Subretinal Transplantation of Human Embryonic Stem Cell-Derived Retinal Tissue in a Feline Large Animal Model
07:43

Subretinal Transplantation of Human Embryonic Stem Cell-Derived Retinal Tissue in a Feline Large Animal Model

Published on: August 5, 2021

1.9K

Enzyme Replacement Therapy in CLN2-Associated Retinopathy.

Claudia Priglinger1, Carolina Courage2, Esther M Maier3,4

  • 1Department of Ophthalmology, University Hospital, Ludwig-Maximilians-University, Munich, Germany.

Klinische Monatsblatter Fur Augenheilkunde
|March 24, 2025
PubMed
Summary

Enzyme replacement therapy with recombinant human TPP1 (rhTPP1) shows promise in slowing retinal degeneration in CLN2 disease, preserving vision and improving quality of life. This intravitreal treatment offers a potential bridging therapy for patients awaiting advanced treatments like gene therapy.

More Related Videos

Intravitreal Injections in the Ovine Eye
03:37

Intravitreal Injections in the Ovine Eye

Published on: July 5, 2022

3.1K
Author Spotlight: Advancing Vision Restoration - Stem Cell-Based Therapy for Retinal Diseases
07:46

Author Spotlight: Advancing Vision Restoration - Stem Cell-Based Therapy for Retinal Diseases

Published on: October 6, 2023

817

Related Experiment Videos

Last Updated: May 6, 2026

Subretinal Transplantation of Human Embryonic Stem Cell-Derived Retinal Tissue in a Feline Large Animal Model
07:43

Subretinal Transplantation of Human Embryonic Stem Cell-Derived Retinal Tissue in a Feline Large Animal Model

Published on: August 5, 2021

1.9K
Intravitreal Injections in the Ovine Eye
03:37

Intravitreal Injections in the Ovine Eye

Published on: July 5, 2022

3.1K
Author Spotlight: Advancing Vision Restoration - Stem Cell-Based Therapy for Retinal Diseases
07:46

Author Spotlight: Advancing Vision Restoration - Stem Cell-Based Therapy for Retinal Diseases

Published on: October 6, 2023

817

Area of Science:

  • Neuroscience
  • Genetics
  • Ophthalmology

Background:

  • Neuronal ceroid lipofuscinoses (Batten disease) are rare genetic neurodegenerative disorders.
  • CLN2 disease, caused by TPP1 gene mutations, leads to progressive vision loss and neurological decline.
  • Current intracerebroventricular enzyme replacement therapy (ERT) for CLN2 disease slows psychomotor decline but not vision loss.

Purpose of the Study:

  • To review current knowledge on ERT for CLN2 retinopathy.
  • To evaluate the safety and efficacy of intravitreal recombinant human TPP1 (rhTPP1) in preserving visual function.
  • To discuss the potential of intravitreal ERT as a bridging therapy.

Main Methods:

  • Review of existing literature on ERT for CLN2 disease.
  • Analysis of a compassionate-use study of intravitreal rhTPP1.
  • Discussion of ongoing and planned clinical trials.

Main Results:

  • Intravitreal rhTPP1 demonstrated safety and efficacy in reducing macular volume loss in a canine model and human patients.
  • The treatment markedly delays retinal degeneration, preserving visual function.
  • ERT for CLN2 retinopathy appears safe and improves patients' quality of life.

Conclusions:

  • Intravitreal rhTPP1 is a safe and effective treatment for CLN2 retinopathy.
  • This therapy can preserve visual function and enhance quality of life for affected individuals.
  • Intravitreal ERT may serve as a crucial bridging therapy until more definitive treatments like gene therapy are available.